Peter Sondermann

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 5 CIPO patents and 12 EPO patents. Top assignees: Suppremol Gmbh, Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Roche Glycart Ag. Active years: 2006-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Sondermann. Retrieved from https://idiyas.com/inventor/peter-sondermann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 18)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Krailling, DE (2006 - 2014)
Rudolfstetten, CH (2014)
Stockdorf, DE (2018 - 2024)

Company Filing History:

Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12048728 - Highly concentrated formulations of soluble Fc receptors (2024-07-30),

2. 11266708 - Highly concentrated formulations of soluble Fc receptors (2022-03-08),

3. 10866247 - In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s) (2020-12-15),

4. 10730946 - Antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor (2020-08-04),

5. 10669324 - Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein (2020-06-02),

6. 10407499 - Anti-Fc-gamma receptor IIB antibodies and uses thereof (2019-09-10),

7. 10352943 - A-fucosylation detection in antibodies (2019-07-16),

8. 10226504 - Highly concentrated formulations of soluble Fc receptors (2019-03-12),

9. 10028998 - Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb (2018-07-24),

10. 9994610 - Separation method for fucosylated antibodies (2018-06-12),

11. 9981009 - Soluble Fcγ receptor for treatment of autoimmune bullous diseases (2018-05-29),

12. 8853363 - Substance binding human IgG Fc receptor IIb (FcγRIIb) (2014-10-07),

13. 8666680 - Recombinant soluble FC receptors (2014-03-04),

14. 7504482 - Recombinant soluble Fc receptors (2009-03-17),

15. 7074896 - Recombinant soluble Fc receptors (2006-07-11),

Title: Inventor Peter Sondermann: A Pioneer in Fc Receptor Formulations

Introduction

Peter Sondermann is an accomplished inventor based in Stockdorf, Germany. With a remarkable portfolio of 15 patents, he stands out in the field of innovative pharmaceutical formulations. His work primarily focuses on soluble Fc receptors, which have significant implications in treating autoimmune diseases and other immune-related conditions.

Latest Patents

Sondermann's most recent patents, notably involve highly concentrated formulations of soluble Fc receptors. These inventions relate specifically to formulations containing high concentrations of the soluble FcγRIIB receptor. The novel formulations are designed to serve as pharmaceutical compounds for addressing various medical conditions, such as autoimmune diseases and infections where the immune system plays a crucial role.

Career Highlights

Throughout his career, Peter Sondermann has made significant contributions to the field of biotechnology. He has been associated with notable organizations, including Suppremol GmbH and the Max Planck Society for the Advancement of Science. His work has greatly influenced advancements in pharmaceutical sciences, particularly in the realm of immune response treatments.

Collaborations

Sondermann has collaborated with esteemed colleagues such as Thomas Pohl and Uwe Jacob. These partnerships have fostered a productive environment, facilitating the exchange of ideas and innovation in developing new scientific solutions.

Conclusion

In conclusion, Peter Sondermann's contributions to the field of soluble Fc receptor formulations exemplify his dedication to advancing medical therapies. His innovative spirit and collaborative efforts have solidified his position as a leading inventor in pharmaceutical science. As he continues to push the boundaries of research, the impact of his inventions will likely resonate in the medical community for years to come.

Profile summary based on public USPTO records.